Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
Author:
Open Access
- 1 January 2018
- journal article
- review article
- Published by Frontiers Media SA in Oncology Reviews
- Vol. 12 (2) , 69-73
Abstract
Precision oncology is now the evidence-based standard of care for the management of many advanced non-small cell lung cancers (NSCLC). Notably, new molecular profiling technologies have permitted dynamic growth in the identification of actionable driver oncogenes including RET rearrangements. RET oncogenes cannot be adequately detected by immunohistochemistry, although fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction and next-generation sequencing are complementary diagnostic tools. In the clinical setting, the benefit of the most developed RET inhibitors, i. e., cabozantinb, vandetanib and lenvatinb, in terms of response and median progressionfree survival has been demonstrated. The absence of striking clinical results of RET inhibitors underscores the clear need for development of more selective and potent RET inhibitors. This paper reviews the clinical data available on RET inhibitors in RET-associated NSCLC.Keywords
This publication has 29 references indexed in Scilit:
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung AdenocarcinomasCancer Discovery, 2013
- Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitorsInternational Journal of Pharmaceutics, 2012
- ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug developmentEuropean Journal of Cancer, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNature Medicine, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- KIF5B-RET fusions in lung adenocarcinomaNature Medicine, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- RET tyrosine kinase signaling in development and cancerCytokine & Growth Factor Reviews, 2005
- PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomasCell, 1990